PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Net income growth under 50% of AGEN's 53.55%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
7.12%
Some D&A expansion while AGEN is negative at -0.49%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
Both cut yoy SBC, with AGEN at -28.14%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-21.66%
Negative yoy working capital usage while AGEN is 66.10%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy AP while AGEN is 259.24%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
161.21%
Growth well above AGEN's 145.40%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
200.00%
Some yoy increase while AGEN is negative at -173.62%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
22.87%
Operating cash flow growth similar to AGEN's 24.15%. Walter Schloss would see parallel improvements or market conditions in cash generation.
-183.51%
Negative yoy CapEx while AGEN is 54.46%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
We reduce yoy invests while AGEN stands at 54.31%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
Negative yoy issuance while AGEN is 330.52%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.